These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 32334592

  • 21. Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.
    Zhang J, Xian TZ, Teng Y, Wang X, Wu MX, Li C, Wang W, Man F, Zhang X, Wang X, Guo LX.
    Int J Clin Pract; 2022; 2022():7128859. PubMed ID: 37214201
    [Abstract] [Full Text] [Related]

  • 22. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study).
    Ikeda K, Takahashi T, Yamada H, Matsui K, Sawada T, Nakamura T, Matsubara H, (for the PEACE Investigators).
    Eur J Prev Cardiol; 2013 Dec; 20(6):1069-79. PubMed ID: 22689416
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes.
    Fayfman M, Galindo RJ, Rubin DJ, Mize DL, Anzola I, Urrutia MA, Ramos C, Pasquel FJ, Haw JS, Vellanki P, Wang H, Albury BS, Weaver R, Cardona S, Umpierrez GE.
    Diabetes Care; 2019 Mar; 42(3):450-456. PubMed ID: 30679302
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial.
    Donate-Correa J, Ferri CM, Mora-Fernández C, Pérez-Delgado N, González-Luis A, Navarro-González JF.
    Cardiovasc Diabetol; 2024 Aug 24; 23(1):314. PubMed ID: 39182114
    [Abstract] [Full Text] [Related]

  • 27. ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL cholesterol levels.
    Jun JE, Choi YJ, Lee YH, Kim DJ, Park SW, Huh BW, Lee EJ, Jee SH, Hur KY, Choi SH, Huh KB.
    Korean J Intern Med; 2018 Jan 24; 33(1):138-147. PubMed ID: 29334727
    [Abstract] [Full Text] [Related]

  • 28. Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study.
    Köseoğlu D, Koparal SS, Özdemir Başer Ö, Berker D.
    Turk J Med Sci; 2021 Feb 26; 51(1):167-174. PubMed ID: 32892547
    [Abstract] [Full Text] [Related]

  • 29. Comparative effects of lipid lowering, hypoglycemic, antihypertensive and antiplatelet medications on carotid artery intima-media thickness progression: a network meta-analysis.
    Huang R, Mills K, Romero J, Li Y, Hu Z, Cao Y, Huang H, Xu Y, Jiang L.
    Cardiovasc Diabetol; 2019 Jan 30; 18(1):14. PubMed ID: 30700294
    [Abstract] [Full Text] [Related]

  • 30. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes.
    Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Tsanikidis H, Vitta I, Karkos C, Karayannacos PE, Gerasimidis T, Liapis CD.
    Exp Clin Endocrinol Diabetes; 2010 Feb 30; 118(2):75-80. PubMed ID: 19834878
    [Abstract] [Full Text] [Related]

  • 31. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
    Blonde L, Pencek R, MacConell L.
    Cardiovasc Diabetol; 2015 Feb 03; 14():12. PubMed ID: 25645567
    [Abstract] [Full Text] [Related]

  • 32. Multiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes.
    Tripolt NJ, Narath SH, Eder M, Pieber TR, Wascher TC, Sourij H.
    Cardiovasc Diabetol; 2014 May 23; 13():95. PubMed ID: 24884694
    [Abstract] [Full Text] [Related]

  • 33. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
    Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I, UTOPIA study investigators.
    Cardiovasc Diabetol; 2020 Jul 09; 19(1):110. PubMed ID: 32646498
    [Abstract] [Full Text] [Related]

  • 34. Effects of comprehensive intensive therapies on the change of intima-media thickness of carotid arteries in type 2 diabetic patients: A report of 4-year follow-up with a literature review.
    Cheng LJ, Xu ZR, Zhang Q, Wang ZD, Wu FW, Yang WX.
    Diab Vasc Dis Res; 2016 Jan 09; 13(1):31-40. PubMed ID: 26499916
    [Abstract] [Full Text] [Related]

  • 35. Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
    Zheng H, Li H, Wang Y, Li Z, Hu B, Li X, Fu L, Hu H, Nie Z, Zhao B, Wei D, Karlson BW, Bots ML, Meng X, Chen Y, Wang Y, METEOR-China Investigators.
    Stroke; 2022 Oct 09; 53(10):3004-3013. PubMed ID: 36017704
    [Abstract] [Full Text] [Related]

  • 36. [Association of glycaemic variability and carotid intima-media thickness in patients with type 2 diabetes mellitus].
    Yang XJ, He H, Lü XF, Wen XR, Wang C, Chen DW, Li XJ, Ran XW.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Sep 09; 43(5):734-8. PubMed ID: 23230750
    [Abstract] [Full Text] [Related]

  • 37. Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial.
    Zhang J, Xian TZ, Wu MX, Li C, Wang W, Man F, Zhang X, Wang X, Pan Q, Guo L.
    J Investig Med; 2022 Oct 09; 70(7):1529-1535. PubMed ID: 35725020
    [Abstract] [Full Text] [Related]

  • 38. Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes.
    Patel YR, Kirkman MS, Considine RV, Hannon TS, Mather KJ.
    Diabetes Metab Res Rev; 2013 Oct 09; 29(7):582-91. PubMed ID: 23908125
    [Abstract] [Full Text] [Related]

  • 39. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
    Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H, Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial.
    Diabetes Care; 2016 Jan 09; 39(1):139-48. PubMed ID: 26628419
    [Abstract] [Full Text] [Related]

  • 40. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study.
    Crouse JR, Bots ML, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Raichlen JS, METEOR Study Group.
    Eur J Cardiovasc Prev Rehabil; 2010 Apr 09; 17(2):223-9. PubMed ID: 20038840
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.